Table 1.
Characteristics of participants with antiretroviral therapy (ART) interruption.
| Characteristics | Number (%) |
|---|---|
| Total | 174 |
| Age | |
| 18–30 | 20 (11.5) |
| 30–50 | 78 (44.8) |
| ≥50 | 76 (43.7) |
| Gender | |
| Male | 115 (66.1) |
| Female | 59 (33.9) |
| Education | |
| Illiterate and primary school | 114 (65.5) |
| Secondary school and above | 60 (34.5) |
| Marital status | |
| Married or living with partner | 117 (67.2) |
| Single | 32 (18.4) |
| Other | 25 (14.4) |
| Route of HIV infection | |
| Heterosexual | 107 (61.5) |
| Homosexual | 7 (4.0) |
| Injecting drug using | 48 (27.6) |
| Other | 12 (6.9) |
| Subtype | |
| CRF01_AE | 35 (20.1) |
| CRF07_BC | 61 (35.1) |
| CRF08_BC | 58 (33.3) |
| B′ | 16 (9.2) |
| Other a | 4 (2.3) |
| CD4+ T cell count at the time of investigation(per uL) | |
| <200 | 70 (40.2) |
| 200–350 | 62 (35.6) |
| ≥350 | 42 (24.2) |
| Antiretroviral regimen before discontinuation | |
| d4T+3TC+EFV/NVP | 1 (0.6) |
| AZT+3TC+EFV/NVP | 66 (37.9) |
| TDF+3TC+EFV/NVP | 83 (47.7) |
| AZT/TDF+3TC+LPV/r | 24 (13.8) |
| Duration of treatment before ART interruption(median, (IQR), months) | 16 (7–26) |
| Duration of ART interruption at survey (median, (IQR), months) | 12 (6–24) |
a includes CRF 55_01B (2, 1.1%), CRF 62_BC (1, 0.6%), Unknown (1, 0.6%). HIV, Human immunodeficiency virus; ART, antiretroviral therapy; IQR, interquartile range; d4T, Stavudine; 3TC, Lamivudine; AZT, Azidothymidine; TDF, Tenofovir; EFV, Efavirenz; NVP, Nevirapine; LPV/r, Lopinavir/r.